Form 4: Immunome Director James Boylan Receives Stock Options

Director James P. Boylan was granted 9,897 stock options in Immunome, Inc. to be held for the benefit of Enavate Sciences, LP.

Summary

• Director James P. Boylan received a grant of 9,897 stock options for Immunome, Inc. (IMNM) on June 10, 2026.
• The options have an exercise price of $18.16 per share.
• The options are set to expire on June 9, 2036.
• The reporting person disclaims beneficial ownership, as the securities are held for the benefit of Enavate Sciences, LP.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine regulatory disclosure regarding director compensation with no material impact on company operations.

Positives

• Alignment of director interests with long-term company performance through equity-based compensation.

Negatives

• None identified in this filing.

Risks

• Vesting is subject to the director's continuous service with the company.

Future Outlook

The options vest in four equal quarterly installments over one year, contingent upon the director's continued service.

Industry Context

StockSavvy.ai notes that director equity grants are standard corporate governance practices in the biotechnology sector to ensure board members are incentivized by shareholder value creation.

Comparison to Industry Standards

• The grant of stock options to non-executive directors is a common practice among mid-cap and small-cap biotech firms to attract and retain board talent.
• The one-year vesting schedule is consistent with standard industry practices for director compensation.

Corporate Governance

Related Party Transactions

• The reporting person holds the securities for the benefit of Enavate Sciences, LP.

Stakeholder Impact

• Minimal impact on shareholders as this is a standard compensation event.

Next Steps

• Vesting of options in quarterly installments starting from June 10, 2026.

Key Dates

Keywords

Immunome, IMNM, Form 4, Director Compensation, Stock Options, Insider Transaction